XML 25 R14.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Note 8 - Stockholders' Deficit | 12 Months Ended
--- | ---
Jun. 30, 2017
Notes to Financial Statements |
Stockholders' Equity Note Disclosure [Text Block] | NOTE 8 - STOCKHOLDERS’ DEFICIT Private Placement – Fiscal 2016 In April 2016, our Board of Directors approved the private placement of up to 7,750,000 shares of our common stock to select accredited investors for a total amount of $3,100,000, or $0.40 per share of common stock. On July 28, 2016, our Board of Directors increased the aggregate amount offered to up to $4,000,000 and extended the termination date to August 31, 2016 ( the “Offering”). During fiscal 2017, we sold 3,687,500 shares of common stock for a total purchase price of $1,475,000 to six accredited investors of which $1,075,000 was received in cash and $400,000 was received via the settlement of outstanding liabilities. Esenjay, our controlling shareholder and primary credit line holder, purchased 1,000,000 shares in exchange for the settlement of $400,000 of debt owed to Esenjay by the Company. Two of the accredited investors who invested an aggregate of $200,000 are siblings of Mr. Johnson. During fiscal 2016, a total of $2,425,000 had been raised of which $1,050,000 was received in cash and $1,375,000 was received via the settlement of outstanding liabilities. Esenjay purchased 625,000 shares for cash proceeds of $250,000 and 3,375,000 shares in exchange for the settlement of $1,350,000 of debt owed to Esenjay by the Company. In addition, we sold 2,000,000 shares (of which 250,000 shares (valued at $100,000 ) were not issued until subsequent to June 30, 2016) to two unrelated accredited investors for $800,000 in cash and 63,000 shares (valued at $25,000 ) in exchange for settlement of accounts payable to a vendor. On April 15, 2016, we entered into an agreement with Esenjay, whereby Esenjay agreed to limit its right of conversion under the Unrestricted Line of Credit to such number of shares so that upon conversion, if any, it will not cause us to exceed our authorized number of shares of common stock. The securities offered and sold in the Offering have not been registered under the Securities Act. The securities were offered and sold to accredited investors in reliance upon exemptions from registration pursuant to Rule 506 promulgated thereunder. The initial closing of the Offering in May 2016 at a price of $0. 40 per share triggered an anti-dilution provision for warrant holders under our 2012 Private Placement pursuant to which an aggregate of 297,035 shares of common stock may be purchased upon exercise. As a result, the exercise price of such warrants was reduced from $2.69 to $1.55 per share. The remaining terms, including expiration dates, of all effected warrants remain unchanged (See Note 9 ). Advisory Agreements Catalyst Global LLC. Effective April 1, 2016, we entered into a renewal contract (the “2016 Renewal”) with Catalyst Global LLC (“CGL”) to provide investor relations services for 12 months in exchange for monthly fees of $2,000 per month and 54,000 shares of unregistered common stock issued as follows: 31,500 shares on June 30, 2016 for services provided during the three months ended June 30, 2016 and 7,500 shares issued upon each of the six -, nine -, and twelve -month anniversaries of the contract. The initial tranche was valued at $0.50 per share or approximately $14,500 when issued on June 30, 2016, the second tranche of 7,500 shares was issued on September 29, 2016 and was valued at $0.40 per share or $3,000, the third tranche of 7,500 shares was issued on January 23, 2017 and was valued at $0.40 per share or $3,000 and the fourth tranche of 7,500 shares was issued on March 20, 2017 and was valued at $0.45 per share or $3,375. Effective April 1, 2017, we entered into a renewal contract (the “2017 Renewal”) with Catalyst Global LLC (“CGL”) to provide investor relations services for 12 months in exchange for monthly fees of $ 3,500 per month and 7,777 shares of restricted common stock per month, issued on a quarterly basis. During the three months ended June 30, 2017, we issued 23,331 shares of common stock to Catalyst valued at $0.45 per share or $10,499. The 2017 Renewal is cancelable upon 60 days written notice. Warrant Activity Warrant detail is reflected below:
|  | Number |  |  | Weighted Average Exercise Price Per Share |  |  | Remaining Contract Term (# years) |
Shares purchasable under outstanding warrants at June 30, 2016 |  |  | 2,804,010 |  |  | $ | 2.00 |  |  |  | 0.39 | - | 2.50 |
Stock purchase warrants expired |  |  | (190,000 | ) |  | $ | 3.00 |  |  |  |  | - |  |
Stock purchase warrants exchanged |  |  | (271,420 | ) |  | $ | 1.40 |  |  |  |  | - |  |
Shares purchasable under outstanding warrants at June 30, 2017 |  |  | 2,342,590 |  |  | $ | 1.97 |  |  |  | 0.12 | - | 1.55 |
In 2012, we issued warrants to certain investors and a consultant (together, the "2012 Warrant Holders") to purchase a total of 297,035 shares of our common stock at $4.10 per share (the "2012 Warrants"). On August 23, 2016, we offered our 2012 Warrant Holders the option to convert their 2012 Warrants for shares of our common stock at a conversion rate of 0.602 shares of common stock per warrant share (the "Warrant Exchange"). As of June 30, 2017, twenty ( 20 ) 2012 Warrant Holders had accepted this offer and accordingly, we have exchanged warrants to purchase 271,420 shares of common stock at an exercise price of $1.40 per share, valued at approximately $10,000, into 163,395 shares of common stock. Stock-based Compensation On November 26, 2014, our board of directors approved our 2014 Equity Incentive Plan (the “2014 Plan”), which was approved by our shareholders on February 17, 2015. The 2014 Plan offers selected employees, directors, and consultants the opportunity to acquire our common stock, and serves to encourage such persons to remain employed by us and to attract new employees. The 2014 Plan allows for the award of stock and options, up to 1 0,000,000 shares of our common stock. Activity in stock options during the year ende d June 30, 2017 and related balances outstanding as of that date are reflected below:
|  | Number of Shares |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contract Term (# years) |
Outstanding at June 30, 2016 |  |  | 900,402 |  |  | $ | 1.13 |  |  |  |  |
Granted |  |  | - |  |  |  |  |  |  |  |  |
Exercised |  |  | - |  |  |  |  |  |  |  |  |
Forfeited and cancelled |  |  | (184,125 | ) |  | $ | 1.63 |  |  |  |  |
Outstanding at June 30, 2017 |  |  | 716,277 |  |  | $ | 1.10 |  |  |  | 7.09 |
Exercisable at June 30, 2017 |  |  | 589,476 |  |  | $ | 1.11 |  |  |  | 6.80 |
Activity in stock options dur ing the year ended June 30, 2016 and related balances outstanding as of that date are reflected below:
|  | Number of Shares |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contract Term (# years) |
Outstanding at June 30, 2015 |  |  | 610,136 |  |  | $ | 1.61 |  |  |  |  |
Granted |  |  | 438,500 |  |  | $ | 0.50 |  |  |  |  |
Exercised |  |  | - |  |  |  |  |  |  |  |  |
Forfeited and cancelled |  |  | (148,234 | ) |  | $ | 1.21 |  |  |  |  |
Outstanding at June 30, 2016 |  |  | 900,402 |  |  | $ | 1.13 |  |  |  | 7.55 |
Exercisable at June 30, 2016 |  |  | 652,590 |  |  | $ | 1.35 |  |  |  | 6.95 |
Stock-based compensation expense recognized in our consolidated statements of operations for the year ended June 30, 2017 and 2016, includes compensation expense for stock-based options and awards granted based on the grant date fair value. For options and awards granted, expenses are amortized under the straight-line method over the expected vesting period. Stock-based compensation expense recognized in the consolidated statements of operations has been reduced for estimated forfeitures of options that are subject to vesting. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Our average stock price during the year ended June 30, 2017, was $0.43, and as a result the intrinsic value of the exercisable options at June 30, 2017, was $2,000. We allocated stock-based compensation expense included in the consolidated statements of operations for employee option grants and non-employee option grants as follows:
Years ended June 30, |  | 201 7 |  |  | 201 6 |
Research and development |  | $ | 13,000 |  |  | $ | 21,000 |
General and administrative |  |  | 27,000 |  |  |  | 88,000 |
Total stock-based compensation expense |  | $ | 40,000 |  |  | $ | 109,000 |
The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. The fair value of stock options was measured at the grant date using the assumptions (annualized percentages) in the table below:
|  | 2017 |  |  | 2016 |
Expected volatility |  |  | 100% |  |  |  |  | 100% |  |
Risk free interest rate |  |  | 1.31% |  |  |  |  | 1.31% |  |
Forfeiture rate |  | 17% | - | 24% |  |  | 17% | - | 24% |
Dividend yield |  |  | 0% |  |  |  |  | 0% |  |
Expected term (years) |  |  | 3 |  |  |  |  | 3 |  |
The remaining amount of unrecognized stock-based compe nsation expense at June 30, 2017 relating to outstanding stock options, is approximately $41,000, which is expected to be recognized over the weighted average period of 1.27 years.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration